MX9606195A - Composicion para inducir una inmuno respuesta mucosica. - Google Patents
Composicion para inducir una inmuno respuesta mucosica.Info
- Publication number
- MX9606195A MX9606195A MX9606195A MX9606195A MX9606195A MX 9606195 A MX9606195 A MX 9606195A MX 9606195 A MX9606195 A MX 9606195A MX 9606195 A MX9606195 A MX 9606195A MX 9606195 A MX9606195 A MX 9606195A
- Authority
- MX
- Mexico
- Prior art keywords
- immune response
- inducing
- antigen
- composition
- site
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se divulga una composicion farmacéutica para inducir una inmuno respuesta protectora a un antígeno en un sitio efecto mucosico en un mamífero huésped. La composicion incluye al menos dos componentes idénticos o diferentes cada uno conteniendo un agente inductor de inmuno respuesta seleccionados del antígeno, con la estipulacion de que el antígeno sea un antígeno de proteína, y un casete de expresion capaz de expresar al antígeno, para administracion concurrente o consecutiva. Uno de los componentes está formulado para entrega nasal/oral para que el agente inductor se enfoque hacia el sitio(s) inductor del inmuno respuesta en la nariz/cavidad oral/faringe o en las glándulas salivales, mientras que el otro componente está formulado para entrega mucosica apropiada diferente de la entrega nasal para que el agente inductor se enfoque hacia el sitio(s) inductor de inmuno respuesta en el sitio efector cuando se desea una respuesta inmune. Dicha composicion también puede incluir opcionalmente un tercer componente que es idéntico o diferente de los dos primeros componentes y está formulado para administracion sistémica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9504433 | 1995-04-07 | ||
| FR9504433A FR2732605B1 (fr) | 1995-04-07 | 1995-04-07 | Composition destinee a l'induction d'une reponse immunitaire mucosale |
| FR95/04433 | 1995-04-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9606195A true MX9606195A (es) | 1998-06-28 |
| MXPA96006195A MXPA96006195A (es) | 1998-10-30 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| CA2192473A1 (en) | 1996-10-10 |
| HUP9700037A2 (hu) | 1998-10-28 |
| HUP9700037A3 (en) | 2002-04-29 |
| NO965207L (no) | 1996-12-05 |
| NZ306483A (en) | 1998-08-26 |
| FR2732605A1 (fr) | 1996-10-11 |
| NO965207D0 (no) | 1996-12-05 |
| US6126938A (en) | 2000-10-03 |
| WO1996031235A1 (fr) | 1996-10-10 |
| EP0765170A1 (fr) | 1997-04-02 |
| FR2732605B1 (fr) | 1997-05-16 |
| JPH10501556A (ja) | 1998-02-10 |
| AU5504996A (en) | 1996-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO965207L (no) | Sammensetning for indusering av mukosal immunrespons | |
| TR200002855T2 (tr) | Raloksifenin solunum yolu ile veya burundan uygulanması. | |
| YU59092A (sh) | Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja | |
| AU672825B2 (en) | Vaccines inducing an immune response against viruses causing porcine respiratory and reproductive diseases | |
| FI953608L (fi) | Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella | |
| BR9106977A (pt) | Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero | |
| WO1995017156A3 (en) | Ethanol substitutes | |
| EE200000536A (et) | Ravimkoostised ja meetodid peroraalsete vaktsiinide ning terapeutiliste ainete süsteemse toime saamiseks | |
| DE69332518D1 (de) | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung | |
| DE69829008D1 (de) | Nasen-, Mund- und Rachenraumkanüle | |
| YU59192A (sh) | Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja | |
| AU5906398A (en) | Dosage composition for nasal delivery and method of use of the same | |
| AU1454988A (en) | Stable pharmaceutical w/o emulsion composition | |
| EP0330227A3 (en) | Derivatives of soluble t-4 | |
| FI894476A0 (fi) | Uusia kosmeettisia koostumuksia, jotka sisältävät uutetta Cichorium intybus L:n ilmaosista, ja niiden valmistus | |
| SE9300581D0 (sv) | Komposition foer nasalbehandling | |
| FI901357A7 (fi) | Suunsisäisen lääkityksen antojärjestelmä | |
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| IL127572A (en) | Pharmaceutical composition and medicament for nasal administration | |
| FI970331L (fi) | Lääkkeen antokoostumus virustenvastaisten aineiden nenään toteutettavaa antoa varten | |
| NZ506422A (en) | Therapeutic uses of keratinocyte growth factor -2 | |
| GR1000419B (el) | Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου. | |
| BR9507451A (pt) | Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo | |
| MC1847A1 (fr) | Fragments d'interferons imnuns recombinants,homogenes et composition pharmaceutiques les contenant | |
| AU6524386A (en) | Method for administering vaccines and compositions therefor |